HK1030887A1 - Treatment of bladder cancer by mycobacterium phleicell wall. - Google Patents
Treatment of bladder cancer by mycobacterium phleicell wall.Info
- Publication number
- HK1030887A1 HK1030887A1 HK01101907A HK01101907A HK1030887A1 HK 1030887 A1 HK1030887 A1 HK 1030887A1 HK 01101907 A HK01101907 A HK 01101907A HK 01101907 A HK01101907 A HK 01101907A HK 1030887 A1 HK1030887 A1 HK 1030887A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- mycobacterium
- phlei
- phleicell
- treatment
- wall
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7511198P | 1998-02-18 | 1998-02-18 | |
PCT/CA1998/001190 WO1999042113A1 (en) | 1998-02-18 | 1998-12-22 | Composition and method for the treatment of bladder cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1030887A1 true HK1030887A1 (en) | 2001-05-25 |
Family
ID=22123625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK01101907A HK1030887A1 (en) | 1998-02-18 | 2001-03-16 | Treatment of bladder cancer by mycobacterium phleicell wall. |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1054680B1 (xx) |
JP (1) | JP4426097B2 (xx) |
CN (1) | CN1153576C (xx) |
AT (1) | ATE290390T1 (xx) |
AU (1) | AU751667B2 (xx) |
CA (1) | CA2321296A1 (xx) |
DE (1) | DE69829316T2 (xx) |
DK (1) | DK1054680T3 (xx) |
ES (1) | ES2238780T3 (xx) |
HK (1) | HK1030887A1 (xx) |
NZ (1) | NZ506406A (xx) |
PT (1) | PT1054680E (xx) |
RO (1) | RO122992B1 (xx) |
WO (1) | WO1999042113A1 (xx) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7501700A (en) * | 1999-09-29 | 2001-04-30 | Bioniche Life Sciences Inc. | Method to disrupt mitochondrial function |
WO2001047561A1 (en) | 1999-12-28 | 2001-07-05 | Bioniche Life Sciences Inc. | Hyaluronic acid in the treatment of cancer |
US20030044352A1 (en) * | 2001-04-24 | 2003-03-06 | Phillips Nigel C. | Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls |
CN101829154B (zh) * | 2010-04-23 | 2012-12-26 | 广西医科大学第一附属医院 | 防治哮喘的药物组合物的制备方法 |
BR112013008727A2 (pt) * | 2010-10-13 | 2016-06-28 | Bioniche Urology Ip Inc | composições de parede celular de ácido ribonucleico micobacteriano e métodos de fabricação e uso das mesmas |
TR201101874A2 (tr) | 2011-02-25 | 2011-08-22 | Leyla A�An Nac�Ye | Yüzeyel mesane tümorü tedavisinde kullanılabilecek mycobacterıum(mikobakteri) brumae hücre duvarı ekstreleri. |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL134371A0 (en) * | 1997-08-05 | 2001-04-30 | Bioniche Life Sciences Inc | Composition and method for regulating cell proliferation and cell death |
-
1998
- 1998-12-22 RO ROA200000832A patent/RO122992B1/ro unknown
- 1998-12-22 DE DE69829316T patent/DE69829316T2/de not_active Expired - Lifetime
- 1998-12-22 CN CNB988136597A patent/CN1153576C/zh not_active Expired - Fee Related
- 1998-12-22 PT PT98962163T patent/PT1054680E/pt unknown
- 1998-12-22 EP EP98962163A patent/EP1054680B1/en not_active Expired - Lifetime
- 1998-12-22 CA CA002321296A patent/CA2321296A1/en not_active Abandoned
- 1998-12-22 WO PCT/CA1998/001190 patent/WO1999042113A1/en active IP Right Grant
- 1998-12-22 AU AU17465/99A patent/AU751667B2/en not_active Ceased
- 1998-12-22 JP JP2000532127A patent/JP4426097B2/ja not_active Expired - Fee Related
- 1998-12-22 DK DK98962163T patent/DK1054680T3/da active
- 1998-12-22 NZ NZ506406A patent/NZ506406A/xx not_active IP Right Cessation
- 1998-12-22 AT AT98962163T patent/ATE290390T1/de active
- 1998-12-22 ES ES98962163T patent/ES2238780T3/es not_active Expired - Lifetime
-
2001
- 2001-03-16 HK HK01101907A patent/HK1030887A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE69829316D1 (de) | 2005-04-14 |
WO1999042113A1 (en) | 1999-08-26 |
JP2002503697A (ja) | 2002-02-05 |
PT1054680E (pt) | 2005-06-30 |
ES2238780T3 (es) | 2005-09-01 |
NZ506406A (en) | 2002-11-26 |
ATE290390T1 (de) | 2005-03-15 |
EP1054680B1 (en) | 2005-03-09 |
CA2321296A1 (en) | 1999-08-26 |
RO122992B1 (ro) | 2010-06-30 |
JP4426097B2 (ja) | 2010-03-03 |
AU751667B2 (en) | 2002-08-22 |
DE69829316T2 (de) | 2006-04-13 |
CN1153576C (zh) | 2004-06-16 |
CN1290171A (zh) | 2001-04-04 |
DK1054680T3 (da) | 2005-06-27 |
EP1054680A1 (en) | 2000-11-29 |
AU1746599A (en) | 1999-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0762898T3 (da) | Cyclodextrinsystem til levering af oligonukleotider til celler | |
IL147017A0 (en) | TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES | |
WO2001024763A3 (en) | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents | |
AU4221399A (en) | Human cd45+ and/or fibroblast + mesenchymal stem cells | |
MY135732A (en) | 5,6-trimethylenepyrimidin - 4 - one compounds | |
MY121548A (en) | Compounds and methods for the treatment of cancer | |
AU2915800A (en) | Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy | |
NZ516349A (en) | Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease | |
SI1297013T1 (sl) | Uporaba TACI kot protitumorskega sredstva | |
IL180924A0 (en) | Method for regulating cell proliferation and cell death | |
WO2001006990A3 (en) | Use of etodolac to treat cancer | |
HK1030887A1 (en) | Treatment of bladder cancer by mycobacterium phleicell wall. | |
MY121046A (en) | Substituted bisindolylmaleimides for the inhibition of cell proliferation | |
DE60120162D1 (en) | Polyamin-analoge als cytotoxische wirkstoffe | |
AU2289400A (en) | 6-arylphenanthridines with pde-iv inhibiting activity | |
AU2107700A (en) | Phenanthridine-n-oxides with pde-iv inhibiting activity | |
WO2004009112A8 (en) | Use of urease for inhibiting cancer cell growth | |
AU7074298A (en) | Activated iododerivatives for the treatment of cancer and aids | |
EP1165106B8 (en) | Composition and method for inducing apoptosis in prostate cancer cells by m-dna and mcc | |
PL331104A1 (en) | Therapeutic application of bam (cd40l) technology in treating diseases related to smooth muscles | |
WO2005032595A3 (en) | Methods and compositions for the inhibition of stat5 in prostate cancer cells | |
EP0799835A3 (en) | Anti-fibroblast growth factor-8 monoclonal antibody | |
PT1135164E (pt) | Metodo para o tratamento de inflamacao | |
Hashimoto et al. | DNA Strand Scissions by Hydroxamic Acids-Copper (II) Ion under Aerobic Conditions. | |
ATE276766T1 (de) | Chemotherapeutische zusammensetzung und verfahren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20131222 |